Wedbush Has Positive Estimate for APLS Q3 Earnings

Key Points

• Wedbush has raised its Q3 2025 EPS estimate for Apellis Pharmaceuticals to $1.42 per share, slightly up from the previous estimate of $1.41, while the consensus full-year earnings estimate is at a loss of $1.70 per share.
• Analysts' target prices for Apellis Pharmaceuticals vary significantly, with Scotiabank lowering their price target from $28.00 to $20.00, while Citigroup and Robert W. Baird raised theirs to $46.00 and $50.00, respectively.
• The stock has experienced a recent positive performance, opening at $22.95 with a market capitalization of $2.88 billion, but notable insider sales have occurred, including significant transactions by the general counsel and CEO.

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Research analysts at Wedbush upped their Q3 2025 earnings per share estimates for Apellis Pharmaceuticals in a report released on Thursday, July 31st. Wedbush analyst L. Chico now anticipates that the company will earn $1.42 per share for the quarter, up from their previous forecast of $1.41. The consensus estimate for Apellis Pharmaceuticals' current full-year earnings is ($1.70) per share. Wedbush also issued estimates for Apellis Pharmaceuticals' FY2027 earnings at $0.12 EPS, FY2028 earnings at $1.27 EPS and FY2029 earnings at $2.56 EPS.

Several other equities analysts have also issued reports on APLS. Wall Street Zen upgraded Apellis Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday, August 2nd. JPMorgan Chase & Co. upped their target price on shares of Apellis Pharmaceuticals from $35.00 to $37.00 and gave the stock an "overweight" rating in a report on Monday. Needham & Company LLC reduced their price objective on shares of Apellis Pharmaceuticals from $40.00 to $29.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Raymond James Financial cut their price target on shares of Apellis Pharmaceuticals from $52.00 to $50.00 and set an "outperform" rating on the stock in a report on Friday, August 1st. Finally, Robert W. Baird increased their target price on Apellis Pharmaceuticals from $47.00 to $50.00 and gave the company an "outperform" rating in a research note on Friday, July 18th. Ten analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, Apellis Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $36.83.

Apellis Pharmaceuticals Stock Performance

Shares of APLS stock traded up $0.13 during trading on Monday, reaching $23.86. The company had a trading volume of 1,037,344 shares, compared to its average volume of 2,292,143. The company has a market capitalization of $3.01 billion, a PE ratio of -13.17 and a beta of 0.78. The company has a debt-to-equity ratio of 2.90, a current ratio of 3.77 and a quick ratio of 3.16. The firm's 50 day simple moving average is $19.18 and its two-hundred day simple moving average is $21.72. Apellis Pharmaceuticals has a one year low of $16.10 and a one year high of $41.94.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The company reported ($0.33) EPS for the quarter, beating analysts' consensus estimates of ($0.44) by $0.11. Apellis Pharmaceuticals had a negative return on equity of 116.09% and a negative net margin of 30.24%. The company had revenue of $171.39 million during the quarter, compared to the consensus estimate of $187.91 million. During the same quarter in the prior year, the firm earned ($0.30) EPS. The company's quarterly revenue was down 10.6% compared to the same quarter last year.

Insider Activity at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, General Counsel David O. Watson sold 5,000 shares of the stock in a transaction that occurred on Wednesday, July 16th. The shares were sold at an average price of $19.55, for a total transaction of $97,750.00. Following the sale, the general counsel directly owned 128,730 shares in the company, valued at $2,516,671.50. This represents a 3.74% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Cedric Francois sold 19,725 shares of the stock in a transaction that occurred on Thursday, July 17th. The stock was sold at an average price of $20.21, for a total value of $398,642.25. Following the sale, the chief executive officer directly owned 331,605 shares of the company's stock, valued at $6,701,737.05. The trade was a 5.61% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 169,090 shares of company stock valued at $3,403,832. 6.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Apellis Pharmaceuticals

A number of large investors have recently bought and sold shares of APLS. GF Fund Management CO. LTD. boosted its position in Apellis Pharmaceuticals by 21.9% during the 1st quarter. GF Fund Management CO. LTD. now owns 3,185 shares of the company's stock worth $70,000 after purchasing an additional 573 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its position in Apellis Pharmaceuticals by 15.6% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,855 shares of the company's stock valued at $84,000 after purchasing an additional 655 shares during the last quarter. Parallel Advisors LLC raised its position in shares of Apellis Pharmaceuticals by 80.0% during the 2nd quarter. Parallel Advisors LLC now owns 1,924 shares of the company's stock worth $33,000 after buying an additional 855 shares in the last quarter. Baird Financial Group Inc. lifted its holdings in shares of Apellis Pharmaceuticals by 1.6% in the first quarter. Baird Financial Group Inc. now owns 55,529 shares of the company's stock valued at $1,214,000 after buying an additional 864 shares during the period. Finally, Amalgamated Bank increased its holdings in shares of Apellis Pharmaceuticals by 12.0% in the second quarter. Amalgamated Bank now owns 8,111 shares of the company's stock valued at $140,000 after buying an additional 866 shares in the last quarter. Institutional investors and hedge funds own 96.29% of the company's stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).